HRP20181343T1 - Postupci i pripravci za induciranje imunosnog odgovora na egfrviii - Google Patents

Postupci i pripravci za induciranje imunosnog odgovora na egfrviii

Info

Publication number
HRP20181343T1
HRP20181343T1 HRP20181343TT HRP20181343T HRP20181343T1 HR P20181343 T1 HRP20181343 T1 HR P20181343T1 HR P20181343T T HRP20181343T T HR P20181343TT HR P20181343 T HRP20181343 T HR P20181343T HR P20181343 T1 HRP20181343 T1 HR P20181343T1
Authority
HR
Croatia
Prior art keywords
egfrviii
preparations
procedures
immune response
inducing immune
Prior art date
Application number
HRP20181343TT
Other languages
English (en)
Croatian (hr)
Inventor
Peter M. Lauer
Keith Bahjat
Original Assignee
Aduro Biotech, Inc.
Providence Health & Services-Oregon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech, Inc., Providence Health & Services-Oregon filed Critical Aduro Biotech, Inc.
Publication of HRP20181343T1 publication Critical patent/HRP20181343T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20181343TT 2010-11-17 2011-11-17 Postupci i pripravci za induciranje imunosnog odgovora na egfrviii HRP20181343T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41485010P 2010-11-17 2010-11-17
EP11841347.5A EP2640842B1 (en) 2010-11-17 2011-11-17 Methods and compositions for inducing an immune response to egfrviii
PCT/US2011/061164 WO2012068360A1 (en) 2010-11-17 2011-11-17 Methods and compositions for inducing an immune response to egfrviii

Publications (1)

Publication Number Publication Date
HRP20181343T1 true HRP20181343T1 (hr) 2018-10-19

Family

ID=46084412

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181343TT HRP20181343T1 (hr) 2010-11-17 2011-11-17 Postupci i pripravci za induciranje imunosnog odgovora na egfrviii

Country Status (17)

Country Link
US (3) US9200057B2 (OSRAM)
EP (1) EP2640842B1 (OSRAM)
JP (1) JP5998370B2 (OSRAM)
CN (1) CN103415620B (OSRAM)
CA (1) CA2818353A1 (OSRAM)
CY (1) CY1120622T1 (OSRAM)
DK (1) DK2640842T3 (OSRAM)
ES (1) ES2684684T3 (OSRAM)
HR (1) HRP20181343T1 (OSRAM)
HU (1) HUE039747T2 (OSRAM)
LT (1) LT2640842T (OSRAM)
PL (1) PL2640842T3 (OSRAM)
PT (1) PT2640842T (OSRAM)
RS (1) RS57630B1 (OSRAM)
SI (1) SI2640842T1 (OSRAM)
SM (1) SMT201800444T1 (OSRAM)
WO (1) WO2012068360A1 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
SI2640842T1 (sl) * 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
SG11201407875UA (en) 2012-06-08 2014-12-30 Aduro Biotech Compostions and methods for cancer immunotherapy
US9511129B2 (en) 2012-11-06 2016-12-06 Aduro Biotech, Inc. Facultatively attenuated bacterial species and methods of preparation and use thereof
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
MX2015008329A (es) 2012-12-27 2016-03-01 Aduro Biotech Inc Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
DK2996473T3 (da) 2013-05-18 2019-11-04 Aduro Biotech Inc Sammensætninger og fremgangsmåder til aktivering af "stimulator af interferon-gen"-afhængig signalering
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
US10258679B2 (en) * 2014-04-24 2019-04-16 Advaxis, Inc. Recombinant Listeria vaccine strains and methods of producing the same
WO2016061115A1 (en) 2014-10-13 2016-04-21 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
JP2017532328A (ja) * 2014-10-14 2017-11-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌治療用の併用療法
US10688166B2 (en) 2014-11-03 2020-06-23 Cerus Corporation Compositions and methods for improved car-T cell therapies
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
AU2016247887A1 (en) * 2015-04-13 2017-11-02 Aduro Biotech, Inc. Epidermal growth factor receptor variant III-mesothelin fusions and methods of using the same
MA44378A (fr) * 2015-04-13 2019-01-23 Aduro Biotech Inc Protéines de fusion immunogènes pour le traitement du cancer
US10455265B2 (en) * 2015-04-27 2019-10-22 Ericsson Ab Program and device class entitlements in a media platform
JP2018515588A (ja) * 2015-05-26 2018-06-14 アドバクシス， インコーポレイテッド 個別化送達ベクターに基づく免疫療法とその使用
MA42263A (fr) * 2015-06-24 2021-03-31 Advaxis Inc Dispositif de fabrication et procédé pour immunothérapie fondée sur un vecteur d'administration personnalisé
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
WO2018026717A1 (en) * 2016-08-01 2018-02-08 Aduro Biotech, Inc. Protein expression enhancer sequences and use thereof
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
AU2018348165B2 (en) 2017-10-10 2025-09-04 Seattle Project Corp. Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
WO2021014398A1 (en) * 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
ATE262586T1 (de) * 1994-11-28 2004-04-15 Univ Jefferson Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
WO2002097044A2 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
EP1513924A4 (en) 2002-05-29 2008-05-21 Univ California ATTENUATED LISTERIA SPP. AND METHOD OF USE THEREOF
AU2003259109A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7833775B2 (en) 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
MX2008005640A (es) * 2005-11-02 2008-12-09 Univ Duke Quimioterapia e inmunoterapia concurrentes.
JP5347135B2 (ja) * 2006-03-01 2013-11-20 アドゥロ バイオテック 遺伝子工学操作されたｌｉｓｔｅｒｉａおよびその使用方法
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US8900816B2 (en) * 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
EP2283112B1 (en) 2008-05-19 2016-10-12 Aduro Biotech Compositions comprising prfa*mutant listeria and methods of use thereof
AU2009273949A1 (en) * 2008-07-24 2010-01-28 Aduro Biotech Compositions and methods for the treatment of hepatitis C
TWI543767B (zh) * 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
SI2640842T1 (sl) * 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII

Also Published As

Publication number Publication date
CN103415620B (zh) 2016-10-12
SI2640842T1 (sl) 2018-09-28
US20140037662A1 (en) 2014-02-06
US20160074491A1 (en) 2016-03-17
CY1120622T1 (el) 2019-12-11
LT2640842T (lt) 2018-09-10
PL2640842T3 (pl) 2018-11-30
US20180021420A1 (en) 2018-01-25
RS57630B1 (sr) 2018-11-30
EP2640842A1 (en) 2013-09-25
CA2818353A1 (en) 2012-05-24
EP2640842B1 (en) 2018-05-30
US9200057B2 (en) 2015-12-01
US9775891B2 (en) 2017-10-03
JP2014504851A (ja) 2014-02-27
DK2640842T3 (en) 2018-08-13
EP2640842A4 (en) 2014-04-09
JP5998370B2 (ja) 2016-09-28
HUE039747T2 (hu) 2019-02-28
CN103415620A (zh) 2013-11-27
ES2684684T3 (es) 2018-10-04
WO2012068360A1 (en) 2012-05-24
SMT201800444T1 (it) 2018-09-13
PT2640842T (pt) 2018-10-12

Similar Documents

Publication Publication Date Title
HRP20181343T1 (hr) Postupci i pripravci za induciranje imunosnog odgovora na egfrviii
IL265707A (en) Pharmaceutical preparations containing human antibodies to pcsk9
IL229663A0 (en) Algal lipid compositions and methods of preparing and utilizing same
HUE037140T2 (hu) Humán GDF8-hoz kötõdõ ellenanyagok
DK2844286T3 (da) Lyofiliserede og vandige anti-CD40-antistofformuleringer
SMT201900181T1 (it) Metodi di preparazione di coniugati
HUE045656T2 (hu) PHF-tau elleni ellenanyagok és alkalmazásuk
DK2914633T3 (da) Antistof/lægemiddel-konjugater og anvendelsesfremgangsmåder
HUE053720T2 (hu) ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
EP2598120A4 (en) COMPOSITIONS AND METHOD FOR CREATING AN IMMUNO TOLERANCE
HRP20190109T1 (hr) Ljudska antitijela na gfr 3 i načini za njihovu primjenu
EP2734049A4 (en) PROBIOTIC COMPOSITIONS AND METHOD
PL2888284T3 (pl) Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
IL230838A0 (en) Pharmaceutical compositions
PL3462173T3 (pl) Przeciwciała przeciwko rysperydonowi i ich zastosowanie
EP2888287A4 (en) ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
EP2931313A4 (en) Solution Formulations of Genetically Engineered Anti- 23P19 Antibodies
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
IL235968B (en) Polysaccharide compositions and methods of use
CO7010828A2 (es) Preparación farmacéutica que comprende ߖciclodextrina sustituida
CO6990713A2 (es) Preparaciones que comprenden emodépsido amorfo
CR20130375A (es) Preparaciones que contienen antraquinona/formulaciones de lignina
PL2908833T3 (pl) Preparaty zawierające wyciągi ziołowe
EP2931042A4 (en) ANTHRACYCLINFORMULIERUNGEN
EP2895186A4 (en) THERAPEUTIC COMPOSITIONS AND RELATED METHODS